Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

Foukakis, T; Papakonstantinou, A; Matikas, A; Bengtsson, NO; Malmstrom, P; Hedayati, E; Steger, GG; Untch, M; Hubbert, L; Johansson, H; Hellstrom, M; Gnant, M; Loibl, S; Greil, R; Moebus, V; Bergh, JCS

View this publication in the PUBMED database